Teva Pharmaceuticals Reports the US FDA’s sBLA Acceptance of Ajovy (Fremanezumab) for Pediatric Episodic Migraine Prevention
Shots:
- The US FDA has accepted sBLA of Ajovy to prevent episodic migraine in children & adolescents (6-17yrs.; ≥45Kg)
- Submission was based on P-III (SPACE) trial assessing Ajovy (SC) vs PBO for 12wks. to treat episodic migraine in 237 pediatric pts, which showed improvements in reducing monthly migraine & headache days
- Ajovy (CGRP antagonist) is available as a 225 mg/1.5 mL single-dose pre-filled syringe or pen, with 2 dosing options: 225mg (QM as 1 injection) or 675mg (Q3M as 3 injections) as SC formulation
Ref: Globenewswire | Image: Teva
Related News:- Alvotech and Teva Launch Selarsdi (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
